QURE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

QU

Mkt Cap

$1.51B

Volume

1.04M

Next Earnings

November 9th

Loading chart

QU

QUREuniQure N.V.

QURE

Pay with—

Available Balance0.00

QU

Mkt Cap

$1.51B

Volume

1.04M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.GlobeNewswire Inc. · Oct 13, 2026

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsLaw firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.GlobeNewswire Inc. · Sep 30, 2026

uniQure Plunges on Additional Data From Huntington's Disease StudyuniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.Zacks Investment Research · Sep 30, 2026

QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.uniQure N.V. experienced a significant stock decline of over 35% on September 29, 2026, following the release of updated 48-month data for AMT-130, its investigational gene therapy for Huntington's disease. The disappointing results have prompted a securities investigation by Kehoe Law Firm on behalf of affected investors.GlobeNewswire Inc. · Sep 29, 2026

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 3, 2026

uniQure Announces Pricing of Upsized $225 Million Public OfferinguniQure N.V. announced the pricing of an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, generating approximately $225 million in gross proceeds. The offering is expected to close on June 25, 2026. The company is advancing gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe conditions.GlobeNewswire Inc. · Jun 24, 2026

Numero AI and Royu Merge to Redefine How Finance Teams OperateNumero AI has acquired Royu in an undisclosed cash-and-stock transaction to combine AI-first fintech capabilities for enterprise finance operations. The merger brings together Royu's engineering expertise with Numero's finance domain knowledge to expand agentic AI systems across accounting close, reconciliation, reporting, order-to-cash, and technical accounting workflows. Royu co-founders Viswajith and Sathya will join Numero's leadership as Chief Product Officer and Chief Technology Officer respectively.Benzinga · May 21, 2026

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors who purchased uniQure N.V. securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resulting in investor losses.GlobeNewswire Inc. · Apr 13, 2026

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanHagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorting comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.GlobeNewswire Inc. · Apr 10, 2026

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanHagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorted comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.GlobeNewswire Inc. · Apr 8, 2026

to start trading

QU

QUREuniQure N.V.

QURE

Pay with—

Available Balance0.00

Your PositionYou don't own any QURE yet.

Related Tickers

Earnings